The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
Fundamentally, my biggest concern with the new rules regards the importance of predictability in business. Strategic planning, essential to running sustainable enterprises, requires the predictability of transparent and forward-looking laws, along with proper due process and accountability.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
NAMPA, Idaho – When Idaho’s largest hospital system bought the state’s largest doctor practice in 2012, the groups expressed hope that the deal would spark a revolution in delivering better-quality care. Instead, it ignited a costly legal battle with state and federal regulators and rival hospital systems. Officials at Boise-based St. Luke’s Health System thought […]
LabCorp (NYSE:LH) finally has the regulatory go-ahead to complete its $85 million acquisition of DNA testing company Orchid Cellmark (NASDAQ:ORCH). The laboratory services and diagnostics firm said that it has reached an agreement with the U.S. Federal Trade Commission that calls for the company to sell off parts of Orchid’s U.S. government paternity business following […]